摘要
目的探讨胃癌中人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)和血管内皮生长因子(vascular endothelial growth factor,VEGF)的表达与胃癌的发生、发展的关系,及作为分子靶点指导胃癌患者临床用药的意义。方法采用免疫组化(immunohistochemistry,IHC)的方法检测103例胃癌患者HER2及VEGF的状态,同时联合荧光原位杂交的方法检测HER2的状态,并与患者的临床资料进行相关性分析。结果①胃癌中HER2扩增率约为11%(11/103),在阳性病例中IHC与荧光原位杂交(fluorescentin situ hydridization,FISH)方法的符合率为90%,具有相关性(P<0.01);②HER2的扩增与胃癌的病理分级、淋巴结转移与否及Lauren分型相关(P<0.05);③胃癌中VEGF表达阳性率约为24%(25/103),VEGF的阳性表达与肿瘤的浸润深度、病理分级、Lauren分型相关(P<0.05);④HER2的表达与VEGF的表达不相关(P>0.05)。结论 HER2、VEGF的阳性表达与胃癌特别是分化较好的胃管状腺癌的发生、发展密切相关。联合检测HER2及VEGF在胃癌(特别是肠型胃癌)中的表达对了解胃癌的发生、发展,及靶向药物曲妥珠单抗和贝伐单抗的选择具有重要意义。
Objective To investigate the relationship between the expression status of human epidermal growth factor receptor 2 （HER2） and （or） vascular endothelial growth factor （VEGF） in gastric cancer and the development and progression of gastric cancers, as well as the molecular target for clinical treatment. To evaluate HER2 and （or） VEGF as of gastric cancer patients. Methods Expression of HER2 and VEGF in 103 patients with gastric cancers were detected by immunohistochemistry. And the gene amplification of HER2 was also detected by fluorescence in situ hybridization （FISH）. Results ①The rate of the gene amplification of HER2 was 11% （11/103）. The expression of HER2 detected by IHC and by FISH which were in well concordance （ coincidence rate was 90% , P〈0.01 ）. ②HER2 expression was significantly higher in well differentiated cancer than that in the poor differentiated and in patients with lymph metastasis than these without lymph metastasis, and so was in Lauren classification intestinal-type group than that in diffuse group （P〈0. 05）. ③Positive expression of VEGF was observed in 25 of 103 （24%） cases, VEGF expression was significantly higher in well differentiated than that in the poor differentiated, in pT3-4 than in pT1-2, and in Lauren classification intestinal-type group than that in diffuse group （ P〈0. 05 ）. ④The expre- ssion of HER2 and VEGF have no relationship （P〉 . 05）. Conclusion Our findings indicated that HER2 and VEGF are involved in the development and progression of gastric cancer, especially for well-differentiated gastrial tubular adenocarcinoma. Detection of HER2 and VEGF together may provide a valuable reference for progression, metastasis, and for the judgment of the biological behavior of this carcinoma, as well as selection of targeted drugs for Trastuzumab and Bevacizumab.
出处
《转化医学杂志》
2013年第1期11-14,共4页
Translational Medicine Journal
基金
广东省医学科研基金(B2011229)
广东省科技计划项目(2009B030801317)
关键词
胃癌
表皮生长因子受体2
血管内皮生长因子
浸润转移
Gastric carcinoma
Human epidermal growth factor receptor 2 （HER2）
Vascular endothelial growth factor （VEGF）
Invasion and metastasis
